MedTrace Logo

Effects of Ondansetron Dose and Timing on Post-operative Nausea and Vomiting

NCT03297021 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 141

Last updated 2020-07-20

Study results available
· View outcomes & findings →

Summary

The aim is to evaluate the effectiveness of three different regimens of prophylactic ondansetron on the incidence and severity of post-operative nausea and vomiting.

Conditions

  • Post-operative Nausea and Vomiting

Interventions

DRUG

Ondansetron 4 MG

dose as per arm selection

DRUG

Ondansetron 8mg

dose as per arm selection

Sponsors & Collaborators

Principal Investigators

  • Daniel Katz, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-23
Primary Completion
2019-04-05
Completion
2019-04-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03297021 on ClinicalTrials.gov